CLINICAL TRIALS PROFILE FOR PROMETHAZINE
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Promethazine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00270777 ↗ | Improving Safety of Antivenom in People Bitten by Snakes | Completed | University of Kelaniya | Phase 4 | 2005-03-01 | A study to increase the safety of polyvalent antivenom involving 1000 patients in three centres: low dose adrenaline, promethazine, & hydrocortisone (alone and in combination) to prevent acute adverse reactions to antivenom in people bitten by snakes: randomised, double blind, placebo-controlled trial. |
| NCT00293215 ↗ | Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2006-02-01 | This was a Phase 1 dose-escalation study of CMD-193, a humanized monoclonal antibody linked to the toxin calicheamicin, in subjects with advanced tumors expressing the Lewis-Y antigen. The primary study objective was to determine the biodistribution and pharmacokinetics (PK) of 111-In-CMD-193 (i.e., CMD-193 tagged with a small amount of radioactive Indium [111-In]), with secondary objectives of determining changes in tumor metabolism and describing the antitumor responses to CMD-193. |
| NCT00293215 ↗ | Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen | Terminated | Ludwig Institute for Cancer Research | Phase 1 | 2006-02-01 | This was a Phase 1 dose-escalation study of CMD-193, a humanized monoclonal antibody linked to the toxin calicheamicin, in subjects with advanced tumors expressing the Lewis-Y antigen. The primary study objective was to determine the biodistribution and pharmacokinetics (PK) of 111-In-CMD-193 (i.e., CMD-193 tagged with a small amount of radioactive Indium [111-In]), with secondary objectives of determining changes in tumor metabolism and describing the antitumor responses to CMD-193. |
| NCT00429832 ↗ | A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department | Completed | GlaxoSmithKline | Phase 4 | 2003-10-01 | This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department. |
| NCT00429832 ↗ | A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department | Completed | University of New Mexico | Phase 4 | 2003-10-01 | This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department. |
| NCT00455234 ↗ | Rapid Tranquillization Trial: TREC-India II | Completed | Christian Medical College, Vellore, India | Phase 3 | 2005-09-01 | Three hundred consecutive adult patients presenting to the emergency services of the department of psychiatry and who are diagnosed by the treating doctor to be needing tranquillization to control agitated or aggressive behavior will be randomized to receive either Injection Olanzepine I.M. or Injection Haloperidol 10mg + Injection Promethazine 50 mg in this parallel group, block randomized, centrally-randomzed, allocation-concealed, assessor-blinded pragmatic clinical trial. The main outcome measure that the two treatments would be compared on would be the clinical state of the patient 4 hours after intervention, but the rate of tranquillization, degree of sedation, proportions tranquil and / or asleep at 15, 30, 60 and 240 minutes, need for additional medication, use of physical restraints, doctors called back, numbers absconding and adverse effects at each of these time points would also be compared. Compliance with oral medication and adverse effects at the end of 2 weeks would also be compared. |
| NCT00541671 ↗ | Prevention of Narcotic-Induced Nausea | Terminated | Christiana Care Health Services | N/A | 2007-02-01 | We are doing this study to find out if extra medicine is needed to avoid the chance of nausea sometimes linked to narcotic pain medicine (for example, morphine, dilaudid, fentanyl). Some doctors always give medicine to prevent the possible side effect of nausea, while others do not. We are looking to see if this extra medicine is helpful in preventing nausea. The goal is to screen all patients with pain and enroll enough subjects to reach our goal of 164 evaluable study participants. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Promethazine
Condition Name
Clinical Trial Locations for Promethazine
Trials by Country
Clinical Trial Progress for Promethazine
Clinical Trial Phase
Clinical Trial Sponsors for Promethazine
Sponsor Name
